Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials

Keyphrases

• Rheumatoid Arthritis 100%
• Combination Therapy 100%
• Network Meta-analysis 100%
• Disease-modifying Antirheumatic Drugs (DMARDs) 100%
• Joint Destruction 100%
• Meta-analysis of Randomized Controlled Trials 100%
• Standardized Mean Difference 47%
• Biological Agents 21%
• Combination Treatment 15%
• Methotrexate 15%
• Tumour Necrosis Factor Inhibitor (TNFi) 15%
• Abatacept 15%
• Low-dose Glucocorticoid 15%
• Tocilizumab 10%
• CD20 Inhibitors 10%
• Randomized Controlled Trial 5%
• Meta-analysis 5%
• Sulfasalazine 5%
• Systematic Meta-analysis 5%
• Disease Treatment 5%
• Joint Erosions 5%
• Joint Damage 5%
• Cyclosporine 5%
• Reporting Item 5%
• Structural Joints 5%
• Indirect Comparison 5%
• Chloroquine 5%
• Leflunomide 5%
• Single Disease 5%
• Cost Difference 5%
• Combination Drug Therapy 5%
• Electronic Archive 5%
• Star-shaped Network 5%
• Biomedical Literature 5%

Nursing and Health Professions

• Rheumatoid Arthritis 100%
• Combination Therapy 100%
• Network Meta-Analysis 100%
• Joint Destruction 100%
• Disease Modifying Antirheumatic Drug 100%
• Biological Product 21%
• Methotrexate 15%
• Tumor Necrosis Factor Inhibitor 15%
• Low Drug Dose 15%
• Abatacept 15%
• Glucocorticoid 15%
• Tocilizumab 10%
• Systematic Review 5%
• Meta Analysis 5%
• Ciclosporin 5%
• Penicillamine 5%
• Chloroquine 5%
• Sulfasalazine 5%
• Combination Drug Therapy 5%
• Leflunomide 5%
• Azathioprine 5%

Immunology and Microbiology

• Inflammatory Arthritis 100%
• Disease-Modifying Antirheumatic Drug 100%
• Biological Product 21%
• Methotrexate 15%
• Low Drug Dose 15%
• Glucocorticoid 15%
• TNF Inhibitor 15%
• Abatacept 15%
• CD20 10%
• Tocilizumab 10%
• Ciclosporin 5%
• Azathioprine 5%
• Sulfasalazine 5%
• Chloroquine 5%
• Leflunomide 5%